Fig. 7
Combination therapy inhibits tumor growth of nasopharyngeal cancer in vivo. (a and b) Loss of NFBD1 signifcantly reduces xenograft growth after PARP inhibitor olaparib treatment. The tumors were measured every week using a digital caliper. Tumor volume = 1/2 × length × width2. (c) Tumor weight at 42 days after treatments, n = 6 mice per condition. *P < 0.05 and **P < 0.01